期刊文献+

1型肺炎兔抗血清的制备及其在多糖含量检测中的质控研究

Preparation of Rabbit Antiserum from Type 1 Pneumonia and its Quality Control in Detection of Polysaccharide Content
下载PDF
导出
摘要 建立一种新的1型肺炎兔抗血清制备方法,并进行型别特异性和方法专属性分析后,用于1型肺炎球菌多糖结合及结合疫苗制备过程中多糖含量的测定。以确定的免疫程序,用自制肺炎1型多糖结合物免疫新西兰白兔,采血后分离血清,免疫血清以免疫双扩散法和ELISA法与商品诊断血清比较;以速率比浊法分析型特异性和方法专属性。建立了自制家兔兔抗血清的制备方法,且该血清优于商品诊断血清,可达到速率比浊法型特异性和相应方法专属性要求,该方法可用于对1型肺炎球菌结合物及结合疫苗多糖含量测定。研究结果为肺炎球菌结合疫苗中多糖含量的检测提供了有力的保障。 The new method of rabbit antiserum from type 1 pneumonia was established, and the type specificity and method specificity were analyzed for the determination of polysaccharide content in the preparation process of type 1 pneumococcal polysaccharide binding and conjugate vaccine. The New Zealand rabbits were immunized with designed immunization schedule.Antisera from rabbits were compared with commercial antiserum according to double immunodiffusion and ELISA results.The specificity of the antisera was assessed with rate nephelometry. The preparation method of rabbit antiserum was established, and the serum was superior to the commercial diagnostic serum, which could meet the requirements of turbidimetric type specificity and corresponding method specificity, and could be used to determine the content of polysaccharides in type 1 pneumococcal conjugates and conjugate vaccines. The results of this study provide a strong guarantee for the determination of polysaccharide content in pneumonia.
作者 赵云霞 江魁 郭爱英 李景艳 ZHAO Yunxia;JIANG Kui;GUO Aiying;LI Jingyan(Hualan Biological Engineering Inc., Henan Xinxiang 453000, China;Hualan Gene Engineering Co. Ltd., Henan Xinxiang 453000, China)
出处 《生物技术进展》 2019年第4期416-421,共6页 Current Biotechnology
关键词 肺炎多糖结合疫苗 家兔兔抗血清 速率比浊法 pneumonic polysaccharide conjugate vaccine rabbit antiserum rate nephelometry
  • 相关文献

参考文献6

二级参考文献44

  • 1王艳萍,缪蕾,钱幼琼,梁娟,吴艳乔,朱军,代礼,周光萱.1996至2000年全国5岁以下儿童死亡监测主要结果分析[J].中华预防医学杂志,2005,39(4):260-264. 被引量:115
  • 2陆权.儿童社区获得性肺炎管理指南(试行)(上)[J].中华儿科杂志,2007,45(2):83-90. 被引量:607
  • 3BUTLER JC, BREIMAN RF, CAMPBELL JF, et al. Pneumo- coccal polysaccharide vaccine efficacy[ J]. JAMA, 1993, 270 (15) :1826 - 1831.
  • 4SHAPIRO ED, BERG AT, AUSTRIAN R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine [ J ]. N Engl J Med, 1991, 325(21 ) :1453 - 1460.
  • 5国家食品药品监督管理局.23价肺炎球菌多糖疫苗制造及枪定试行规程YBS00092005[S].2005:1-9.
  • 6国家食品药品监督管理局.23价肺炎球菌多糖疫苗药晶标准WS4-(S-004),2010Z[S].2010:1-12.
  • 7LEXAU CA, LYNFIELD R, DANILA R, et al. Changing epide- miology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine[ J ]. JAMA, 2005, 294(16) :2043 -2051.
  • 8SMITH KJ, ZIMMERMAN RK, LIN C J, et al. Alternative strat- egies for adult pneumococcal polysaccharide vaccination: a cost- effectiveness analysis [ J ]. Vaccine, 2008, 26 ( 11 ) : 1420 - 1431.
  • 9国家食品药品监督管理局药品认证中心.药品GMP指南.质量管理体系[M].北京:中国医药科技出版社,2011:164-171.
  • 10Robbins JB,Schneerson R,Shousun CZ.Perspective hypothesis:serum IgG antibody is sufficien to confer protection against infections diseases by inactivating theinoculum.J Infect Dis,1995,171(6):1387-1398.

共引文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部